- Email: [email protected]
Biologics and biomarkers for asthma, urticaria, and nasal polyposis
Continuing Medical Education examination
Biologics and biomarkers for asthma, urticaria, and nasal polyposis Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma & Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: mai00303 Contact hours: 1.0 Expiration date: April 30, 2018 Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instructions, visit the Journal’s Web site at www.jacionline.org.
The Editors thank the Baylor College of Medicine Allergy/Immunology Training Program for developing this CME examination. The individuals (listed alphabetically) who contributed to its preparation were Aba Al-Kaabi, MD, Maya Gharfeh, MD, MPH, An Nguyen, MD, Zachary W. Marshall, MD, Dipika Patel, MD, Cecilia Poli, MD, and Chih-Yin Yeh, MD, under the direction of Lenora M. Noroski, MD, MPH, and William T. Shearer, MD, PhD. The CME examination authors disclosed the following relationships: The examination authors disclosed no relevant financial relationships.
Learning objectives: ‘‘Biologics and biomarkers for asthma, urticaria, and nasal polyposis’’ 1. To understand the immunopathologic mechanisms underlying different phenotypes of allergic disorders. 2. To describe the mechanism of action of the biologic agents available for treatment of the allergic diseases of asthma, nasal polyposis, and urticaria. 3. To distinguish the biologic agent associated with clinical improvement in different allergic phenotypes with distinct underlying mechanisms. CME items Question 1. Which of the following cytokines is pivotal in neutrophilic asthma? A. IL-4 B. IL-5 C. IL-8 D. IL-13 Question 2. Which of the following types of inflammation is most likely to be seen in patients with type 2 (T2) asthma? A. eosinophilic inflammation B. neutrophilic inflammation C. paucigranulocytic inflammation D. basophilic inflammation Question 3. Dupilumab is an mAb that has been shown to have good clinical effect in patients with asthma, atopic dermatitis, and nasal polyposis through targeting which of the following molecules? A. IL-4 receptor a chain B. IL-2 receptor a chain C. IL-12P40 chain D. FcεRI 1422
May 2017
Question 4. Which biologic agent has shown promising effects in decreasing nasal polyp scores and reducing the need for sinus surgery after being administered for 6 months in the event of prominent nasal polyp and mucosal eosinophilia? A. mepolizumab B. reslizumab C. dupilumab D. omalizumab Question 5. Which of the following biologics is approved for the treatment of Muckle-Wells syndrome? A. rilonacept B. abatacept C. imatinib D. etanercept
J ALLERGY CLIN IMMUNOL
Biologics and biomarkers for asthma, urticaria, and nasal polyposis Instructions for category 1 Continuing Medical Education credit The American Academy of Allergy, Asthma & Immunology is accredited as a provider of Continuing Medical Education (CME) by the Accreditation Council for Continuing Medical Education. Test ID no.: mai00303 Contact hours: 1.0 Expiration date: April 30, 2018 Category 1 credit can be earned by reading the text material and taking this CME examination online. For complete instructions, visit the Journal’s Web site at www.jacionline.org.
The Editors thank the Baylor College of Medicine Allergy/Immunology Training Program for developing this CME examination. The individuals (listed alphabetically) who contributed to its preparation were Aba Al-Kaabi, MD, Maya Gharfeh, MD, MPH, An Nguyen, MD, Zachary W. Marshall, MD, Dipika Patel, MD, Cecilia Poli, MD, and Chih-Yin Yeh, MD, under the direction of Lenora M. Noroski, MD, MPH, and William T. Shearer, MD, PhD. The CME examination authors disclosed the following relationships: The examination authors disclosed no relevant financial relationships.
Learning objectives: ‘‘Biologics and biomarkers for asthma, urticaria, and nasal polyposis’’ 1. To understand the immunopathologic mechanisms underlying different phenotypes of allergic disorders. 2. To describe the mechanism of action of the biologic agents available for treatment of the allergic diseases of asthma, nasal polyposis, and urticaria. 3. To distinguish the biologic agent associated with clinical improvement in different allergic phenotypes with distinct underlying mechanisms. CME items Question 1. Which of the following cytokines is pivotal in neutrophilic asthma? A. IL-4 B. IL-5 C. IL-8 D. IL-13 Question 2. Which of the following types of inflammation is most likely to be seen in patients with type 2 (T2) asthma? A. eosinophilic inflammation B. neutrophilic inflammation C. paucigranulocytic inflammation D. basophilic inflammation Question 3. Dupilumab is an mAb that has been shown to have good clinical effect in patients with asthma, atopic dermatitis, and nasal polyposis through targeting which of the following molecules? A. IL-4 receptor a chain B. IL-2 receptor a chain C. IL-12P40 chain D. FcεRI 1422
May 2017
Question 4. Which biologic agent has shown promising effects in decreasing nasal polyp scores and reducing the need for sinus surgery after being administered for 6 months in the event of prominent nasal polyp and mucosal eosinophilia? A. mepolizumab B. reslizumab C. dupilumab D. omalizumab Question 5. Which of the following biologics is approved for the treatment of Muckle-Wells syndrome? A. rilonacept B. abatacept C. imatinib D. etanercept
J ALLERGY CLIN IMMUNOL